



Published in final edited form as:

*Pharm Res.* ; 36(7): 108. doi:10.1007/s11095-019-2638-z.

## Correction to: Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharmaceutical Research.

Pavan Kumar Prathipati<sup>1</sup>, Subhra Mandal<sup>1</sup>, Gregory Pon<sup>1</sup>, Renuga Vivekanandan<sup>2</sup>, Christopher J. Destache<sup>1,2</sup>

There are errors in the published article (Volume 34, Number 12, pp. 2749–2755).

The errors occurred in pharmacokinetic study design of materials and methods section on page 2750–51.

1. Another group of 15 mice (3 mice/time point) were injected SubQ with 200 mg/kg (each TAF, **FTC**, and EVG) of free drug in 1 mL of 5% dextrose.

FTC is not related to the objective of this article and it has no reported drug-drug interactions that could affect PK of TAF and EVG [1].

### References

1. AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018.
2. Institutional Animal Care and Use Committee approved protocol (#0989) and procedures were followed. However, the authors retrospectively found that “injecting naïve TAF+FTC+EVG solution to mice” was not in the approved protocol.

Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1>

**Publisher's Disclaimer:** This Author Accepted Manuscript is a PDF file of a an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.